-
(单词翻译:双击或拖选)
As the pandemic enters its 4th year, there's still much to learn about long COVID
Researchers estimate at least 65 million people worldwide have suffered from long COVID. NPR's Steve Inskeep talks to Dr. Eric Topol about a paper he co-authored on what we know about long COVID.
STEVE INSKEEP, HOST:
Dr. Eric Topol has been studying one of the toughest problems of the pandemic - long COVID, people who suffer for months or years instead of days.
ERIC TOPOL: Because it's varied2, because there's a diverse - almost every organ system in the body can be affected3, there's unwillingness4 to understand this picture.
INSKEEP: Researchers estimate that at least 65 million people worldwide have suffered from long COVID. They may report heart problems or blood clots5, fatigue6, trouble breathing, autoimmune disorders7, even diabetes8. Diseases that tend to affect older people strike people under 40.
TOPOL: There's been many who - in the medical community who have been trying to deny long COVID's existence because we don't have a simple blood test to make the diagnosis9 like we do for many other clinical conditions. And eventually we will have such a test. But right now, of course, this is all a work in progress.
INSKEEP: Dr. Topol led some of that work in progress. He's a professor of molecular10 medicine at Scripps Research. For the journal Nature, he co-authored a study of studies gathering11 the available literature to help document long COVID and think through what to do about it.
TOPOL: There are many studies now to show that in some people with long COVID, they have reservoirs of the virus. That is, they have remnants of the virus or even intact replication-competent virus in the gastrointestinal tract12 or other parts of the body. So they are harboring the virus as a trigger to promote more inflammation, more immune response. And so that isn't necessarily in all people with long COVID, but it has been documented in many. And also it's of interest that one of the drugs we use to treat COVID, Paxlovid, has, in many case reports, helped people with long COVID. And that might be tied into those people who still have a reservoir of virus in their body.
INSKEEP: What are other approaches to treatment?
TOPOL: Well, no treatment has been validated13 to be effective yet. And so in our review, we list, you know, the many candidate treatments that can be pursued with definitive14 trials - everything from pacing to try to have the amount of physical activity modulated15 to hyperbaric oxygen chambers16, to ganglion blocks, all sorts of different drugs, apheresis of the blood. There's many different treatments, some of them relatively17 practical, some of them very inaccessible18, expensive. But they need to be assessed because so many of these people are in a desperate, disabling condition. These are people who previously19 were healthy, often, you know, quite athletic20 and now incapable21 of their daily life activity.
INSKEEP: Is this correct that you produced this paper with people who have long COVID?
TOPOL: Yeah, this is something, you know, I'm especially proud of because when the journal asked for a comprehensive review, I turned to three people who I think are the most extraordinary leaders in the long COVID space, who actually each have long COVID. They know it personally, and they have been studying this to try to come up with better treatments, better understanding of long COVID. So, you know, Hannah Davis, Lisa McCorkle, Julia Moore Vogel are exemplary researchers who I had the privilege to work with.
INSKEEP: How, if at all, do you think it shaped your findings that you were working with people who are experiencing this themselves?
TOPOL: Well, we don't have enough respect for patients themselves with a condition where you learn from them. And I think this is - perhaps the best way is to have people who are much more familiar with how this virus can affect individuals with objective review of the literature and, of course, the peer review system so that it's not written by people who don't really know the condition.
INSKEEP: Is this a case where the patients, in effect, have known more than the doctors?
TOPOL: There isn't any question of that. Unfortunately, today, too many people who have bona fide long COVID, who are suffering - they'll go to a doctor, and the doctor will just dismiss it. And where there are long COVID clinics, they're oversubscribed and hard to get in. So the lack of the medical communities dealing22 with this inconvenient23 truth - we have to get over that. We've got to support these folks. We've got to come up with better treatments. And what can't be emphasized enough - there's only one way of preventing long COVID, which is not to get COVID in the first place. And that's another reason not to let our guard down as the pandemic and the virus continues its course.
INSKEEP: Eric Topol, thanks so much.
TOPOL: Thank you, Steve. Great to talk with you.
1 transcript | |
n.抄本,誊本,副本,肄业证书 | |
参考例句: |
|
|
2 varied | |
adj.多样的,多变化的 | |
参考例句: |
|
|
3 affected | |
adj.不自然的,假装的 | |
参考例句: |
|
|
4 unwillingness | |
n. 不愿意,不情愿 | |
参考例句: |
|
|
5 clots | |
n.凝块( clot的名词复数 );血块;蠢人;傻瓜v.凝固( clot的第三人称单数 ) | |
参考例句: |
|
|
6 fatigue | |
n.疲劳,劳累 | |
参考例句: |
|
|
7 disorders | |
n.混乱( disorder的名词复数 );凌乱;骚乱;(身心、机能)失调 | |
参考例句: |
|
|
8 diabetes | |
n.糖尿病 | |
参考例句: |
|
|
9 diagnosis | |
n.诊断,诊断结果,调查分析,判断 | |
参考例句: |
|
|
10 molecular | |
adj.分子的;克分子的 | |
参考例句: |
|
|
11 gathering | |
n.集会,聚会,聚集 | |
参考例句: |
|
|
12 tract | |
n.传单,小册子,大片(土地或森林) | |
参考例句: |
|
|
13 validated | |
v.证实( validate的过去式和过去分词 );确证;使生效;使有法律效力 | |
参考例句: |
|
|
14 definitive | |
adj.确切的,权威性的;最后的,决定性的 | |
参考例句: |
|
|
15 modulated | |
已调整[制]的,被调的 | |
参考例句: |
|
|
16 chambers | |
n.房间( chamber的名词复数 );(议会的)议院;卧室;会议厅 | |
参考例句: |
|
|
17 relatively | |
adv.比较...地,相对地 | |
参考例句: |
|
|
18 inaccessible | |
adj.达不到的,难接近的 | |
参考例句: |
|
|
19 previously | |
adv.以前,先前(地) | |
参考例句: |
|
|
20 athletic | |
adj.擅长运动的,强健的;活跃的,体格健壮的 | |
参考例句: |
|
|
21 incapable | |
adj.无能力的,不能做某事的 | |
参考例句: |
|
|
22 dealing | |
n.经商方法,待人态度 | |
参考例句: |
|
|
23 inconvenient | |
adj.不方便的,令人感到麻烦的 | |
参考例句: |
|
|